These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9292396)

  • 21. Carvedilol in heart failure.
    Kelly DT
    Cardiology; 1993; 82 Suppl 3():45-9. PubMed ID: 8106165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
    Zehender M; Just H
    Z Kardiol; 1996; 85 Suppl 7():23-9. PubMed ID: 9082680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carvedilol--a wide therapeutic potential in cardiovascular syndromes. Introduction.
    Taylor SH; Storstein L
    Cardiology; 1993; 82 Suppl 3():1-2. PubMed ID: 8106157
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of carvedilol on mortality and morbidity in patients with chronic heart failure.
    Circulation; 1996 Aug; 94(4):592. PubMed ID: 8772669
    [No Abstract]   [Full Text] [Related]  

  • 26. Carvedilol and metoprolol European trial: do the results merit challenge?
    Smith KM
    Am J Health Syst Pharm; 2004 Jun; 61(12):1289-93. PubMed ID: 15259762
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.
    Giugliano D; Acampora R; Marfella R; De Rosa N; Ziccardi P; Ragone R; De Angelis L; D'Onofrio F
    Ann Intern Med; 1997 Jun; 126(12):955-9. PubMed ID: 9182472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.
    Serruys PW; Foley DP; Höfling B; Puel J; Glogar HD; Seabra-Gomes R; Goicolea J; Coste P; Rutsch W; Katus H; Bonnier H; Wijns W; Betriu A; Hauf-Zachariou U; van Swijndregt EM; Melkert R; Simon R
    Circulation; 2000 Apr; 101(13):1512-8. PubMed ID: 10747343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
    Yue TL; Mckenna PJ; Lysko PG; Gu JL; Lysko KA; Ruffolo RR; Feuerstein GZ
    Eur J Pharmacol; 1994 Jan; 251(2-3):237-43. PubMed ID: 8149979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol.
    Celik T; Iyisoy A; Jata B; Celik M; Gunay C; Isik E
    Int J Cardiol; 2009 Jul; 135(3):393-6. PubMed ID: 18279982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carvedilol decreases elevated oxidative stress in human failing myocardium.
    Nakamura K; Kusano K; Nakamura Y; Kakishita M; Ohta K; Nagase S; Yamamoto M; Miyaji K; Saito H; Morita H; Emori T; Matsubara H; Toyokuni S; Ohe T
    Circulation; 2002 Jun; 105(24):2867-71. PubMed ID: 12070115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Severe heart failure--effects of carvedilol therapy. The Copernicus Study].
    Kindermann M; Böhm M
    Internist (Berl); 2002 Feb; 43(2):284-6. PubMed ID: 11963765
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antioxidant and antiarrhythmic activity of carvedilol in patients with ischemic heart disease. Comparison with anaprilin].
    Vasil'ev AP; Strel'tsova NN; Gorbunova TIu; Mal'tseva IA; Zykova EL
    Ter Arkh; 2001; 73(10):65-7. PubMed ID: 11763521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of carvedilol and propranolol on coronary blood flow.
    Sievert H; Frey G; Schräder R; Schmidt T; van der Does R; Kaltenbach M; Kober G
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S122-4. PubMed ID: 1974502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure.
    Krum H; Gu A; Wilshire-Clement M; Sackner-Bernstein J; Goldsmith R; Medina N; Yushak M; Miller M; Packer M
    Am Heart J; 1996 Feb; 131(2):337-41. PubMed ID: 8579030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are all beta-blockers for heart failure the same?
    Cleland JG
    Circulation; 2000 Aug; 102(6):E41-2. PubMed ID: 10931819
    [No Abstract]   [Full Text] [Related]  

  • 37. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
    Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
    J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Info-congress. COPERNICUS and Val-HEFT studies].
    Kulbertus H
    Rev Med Liege; 2000 Nov; 55(11):1018-20. PubMed ID: 11195705
    [No Abstract]   [Full Text] [Related]  

  • 39. Further insights into coronary debulking: the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.
    Thury A; Van Langenhove G; Wardeh AJ; Foley DP; Serruys PW
    Semin Interv Cardiol; 2000 Dec; 5(4):185-92. PubMed ID: 11244515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.
    Yue TL; Mckenna PJ; Gu JL; Cheng HY; Ruffolo RR; Feuerstein GZ
    Hypertension; 1993 Dec; 22(6):922-8. PubMed ID: 7902335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.